Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study - Bois A du; Moiseenko V; Biakhov M; Eiermann W; Ströhlein M; Makhson A; Lichinitser M; Pfisterer J; Schmalfeldt B; Sommer H; Gorbounova V; Burges A; et al. (Cancer Cell International, 2004)